<SEC-DOCUMENT>0001818382-24-000054.txt : 20240510
<SEC-HEADER>0001818382-24-000054.hdr.sgml : 20240510
<ACCEPTANCE-DATETIME>20240510070622
ACCESSION NUMBER:		0001818382-24-000054
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240510
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240510
DATE AS OF CHANGE:		20240510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Humacyte, Inc.
		CENTRAL INDEX KEY:			0001818382
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				851763759
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39532
		FILM NUMBER:		24932856

	BUSINESS ADDRESS:	
		STREET 1:		2525 EAST NORTH CAROLINA HIGHWAY 54
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713
		BUSINESS PHONE:		919-313-9633

	MAIL ADDRESS:	
		STREET 1:		2525 EAST NORTH CAROLINA HIGHWAY 54
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alpha Healthcare Acquisition Corp.
		DATE OF NAME CHANGE:	20200716
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>huma-20240510.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:108c879a-0b18-4eb5-9e60-c4f914c1e995,g:53f6320e-4e8c-4684-ba76-530d54434ca8,d:df3f5b6290044cd489fdbaa8771051bb-->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>huma-20240510</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001818382</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-26">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="huma-20240510.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-10</xbrli:startDate><xbrli:endDate>2024-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-10</xbrli:startDate><xbrli:endDate>2024-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-10</xbrli:startDate><xbrli:endDate>2024-05-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="idf3f5b6290044cd489fdbaa8771051bb_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):&#160; <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May 10, 2024</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Humacyte, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-39532</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">85-1763759</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.810%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">2525 East North Carolina Highway 54</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Durham,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">NC</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">27713</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">919</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">313-9633</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.628%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.832%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which<br/>registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-18">HUMA</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-20">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-21">HUMAW</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-22">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-23">x</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-24">o</ix:nonNumeric></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="idf3f5b6290044cd489fdbaa8771051bb_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;10, 2024, Humacyte, Inc. issued a press release regarding its financial results for its fiscal first quarter ended March&#160;31, 2024. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained herein, including the exhibit attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div id="idf3f5b6290044cd489fdbaa8771051bb_10"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:79.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="huma-20240510xexx991.htm">Press release, dated May 10, 2024.</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="idf3f5b6290044cd489fdbaa8771051bb_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HUMACYTE, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date:  May 10, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/ Dale A. Sander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dale A. Sander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Chief Corporate Development Officer and Treasurer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>huma-20240510xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i43b603aa49c74459ad051caa58652a22_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:10pt;text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:63px;margin-bottom:5pt;vertical-align:text-bottom;width:336px"></div><div style="margin-top:16pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Humacyte </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Quarter 2024 Financial Results and Business Update</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biologics License Application (BLA) for HAV&#8482; Accepted by FDA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BLA Granted Priority Review for Vascular Trauma Indication&#59; PDUFA date set for August 10, 2024</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Raised approximately $43 million in net proceeds from public offering of common stock</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference call and live webcast at 8&#58;00 a.m. ET today</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DURHAM, N.C., May&#160;10, 2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> &#8211; </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humacyte, Inc. (Nasdaq&#58; HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tissue at commercial scale, today announced financial results for the first quar</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ter ended March&#160;31, 2024 and highlighted recent accomplishments </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advancing the investigational Human Acellular Vessel</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (HAV) closer to planned U.S. market launch.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2024, we achieved a major milestone with the acceptance by the Food and Drug Administration (FDA) of our Biologics License Application (BLA) seeking approval of the HAV in the vascular trauma indication,&#8221; said Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte. &#8220;The FDA&#8217;s decision to grant Priority Review sets a Prescription Drug User Fee Act (PDUFA) date of August 10, 2024, and the entire Humacyte team is working to support our planned U.S. market launch. Among our recent accomplishments is the completion of a Budget Impact Model illustrating the potential economic value of the HAV compared to current standard of care in vascular trauma. In addition, the FDA completed its Pre-Licensing Inspection of our manufacturing facilities in Durham, North Carolina as part of the BLA review process. We remain on track with our BLA review and commercial launch preparations and remain confident in the approvability of the HAV in vascular trauma.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Quarter </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> and Recent Corporate Highlights</font></div><div style="margin-top:12pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HAV in Vascular Trauma</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Biologics License Application for HAV Granted Priority Review by U.S. FDA for the Vascular Trauma Indication </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; In February 2024, the FDA accepted and granted Priority Review to Humacyte&#8217;s BLA seeking approval of the HAV in urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and when autologous vein use not feasible. The BLA submission is supported by positive results from the V005 Phase 2&#47;3 clinical trial, as well as real-world evidence from the treatment of wartime injuries in Ukraine under a humanitarian aid program. The HAV was observed to have higher rates of patency, or blood flow, and lower rates of amputation and infection, as compared to historic synthetic graft benchmarks.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Preparation for Planned U.S. Launch of HAV in Vascular Trauma </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Building upon the positive clinical results and the Priority Review grant by the FDA, Humacyte has implemented a company-wide, multi-disciplinary program designed to ensure U.S. launch readiness upon the anticipated approval of the HAV for the vascular trauma indication. Major recent milestones include the completion of a Budget Impact Model illustrating the potential economic value of the HAV compared to current standard of care. Presentations of clinical results and the Budget Impact Model are planned at upcoming medical meetings and in publications during the remainder of 2024. Other ongoing activities to build awareness include demonstrations of the HAV by Humacyte&#8217;s Medical Affairs team at medical and military </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conferences, and at meetings conducted across the U.S. at Trauma medical centers. The Company has also begun the process to procure an ICD-10 PCS code for the HAV with the Centers for Medicare &#38; Medicaid Services (CMS). We have also commenced the recruiting of a high-quality sales team to support the planned market launch. Humacyte is pleased to announce that we have hired Morgan Rankin as Vice President of Sales, joining Humacyte after 12 years at Teleflex Medical. Morgan most recently served as Vice President of Sales, Trauma and Emergency Medicine at Teleflex where she led a team of approximately 100 sales professionals focused on vascular access and hemorrhage control.</font></div><div style="margin-top:12pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical and Scientific Presentations</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Presentation Highlighting Advancement of the HAV in Dialysis Access</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; in April 2024, Humacyte completed one year of follow-up in our Phase 3 clinical trial in arteriovenous (AV) access for hemodialysis comparing the HAV to the current standard of care, autologous arteriovenous fistula. Top line results are expected in the third quarter of this year. In addition, in collaboration with our corporate partner Fresenius Medical Care and its subsidiary Frenova Renal Research, Humacyte conducted a study to review the outcomes of close to 180,000 adult patients who received in-center dialysis at Fresenius Kidney Care dialysis centers. Among the areas of study were the complications and cost of treatment by patient demographic. The objective of the study was to further define patient subgroups who could most benefit from the HAV. Results from the study were presented by clinicians at a virtual KOL event in March 2024 titled &#8220;Hemodialysis Access&#58; A Crossroads of Care&#8221; (a replay of the webinar is available here https&#58;&#47;&#47;lifescievents.com&#47;event&#47;humacyte-2&#47;). In the study women, particularly obese and diabetic women, were observed to have higher complication rates, including infections and access failures, and that these factors drive substantially higher treatment costs. The cost of maintaining dialysis access in patients, including costs of infections and fistula failures, average approximately $22,000 to $55,000 per year. In addition, data indicate that vascular access costs for the upper quintile of patients exceed approximately $91,000 per year. Based on the results of this research, Humacyte has commenced a clinical study designed to demonstrate the anticipated clinical and health economic benefits of the HAV in female dialysis patients, a high-unmet-need population.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Advancement of Diabetes Program</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Results from ongoing preclinical studies support the potential of Humacyte&#8217;s BioVascular Pancreas (BVP&#8482;) product candidate to enable the delivery and survival of insulin-producing islets as a potential treatment for type 1 diabetes. In three-month studies conducted in non-human primates, researchers observed that insulin-producing cells in the BVP survive after implantation and continue to make insulin. In addition, Humacyte has advanced the manufacturing of islets from human stem cells and has observed that these islets can arrest diabetes in rodent models. These and other preclinical results will be presented at several upcoming scientific conferences, including the American Diabetes Association Annual Meeting 2024 to be held June 21-24, 2024.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">CABG Preclinical Remodeling Results </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical six-month studies have been conducted in non-human primates to support the planned advancement of the small-diameter HAV into human clinical trials in cardiac bypass graft surgery (CABG).</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humacyte has observed remodeling of the HAV to a diameter that closely matches that of the native coronary vessels, which is an outcome not observed with any other conduit.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These promising results of HAV patency and remodeling will be presented at the Tissue Engineering and Regenerative Medicine (TERM-2024) Conference on June 11-12, 2024.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HAV and BVP are investigational products and have not been approved for sale by the FDA or any other regulatory agency.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Quarter </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Financial Highlights</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company reported cash and cash equivalents of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$115.5 million</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of March&#160;31, 2024. Total net cash provided was $35.1 million for the first three months of 2024, compared to net cash used of $20.2 million for the first three months of 2023. The increase in net cash provided resulted primarily from the receipt of approximately $43.0 million in net proceeds from an underwritten public offering of Humacyte&#8217;s common stock in March 2024, and $20 million in proceeds from an additional draw under its previously disclosed funding arrangement with Oberland Capital Management. Humacyte believes that its cash and cash equivalents will be adequate to finance operations for at least 12 months from the date of this financial report, well past the currently anticipated timelines for FDA approval of commercialization of the HAV in the vascular trauma indication.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There was no revenue for either the first quarter of 2024 or the first quarter of 2023.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The overall operating expense run rate for the first quarter of 2024 is virtually identical to the fourth quarter of 2024. Total operating expenses, which includes non-cash expenses, were $26.6 million for the first quarter of 2024, largely unchanged compared to $26.2 million incurred for the 4th quarter of 2023.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development expenses were $21.3 million for the first quarter of 2024, compared to $17.3 million for the first quarter of 2023. The current-period increase resulted primarily from increased materials and personnel expenses to support expanded research and development initiatives and our clinical trials, including the expansion of clinical development of the HAV for use in AV access for hemodialysis.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were $5.3 million for the first quarter of 2024, compared to $5.2 million for the first quarter of 2023. The slight increase during the three months ended March&#160;31, 2024 compared to the prior-year period resulted primarily from increased professional fees and external services costs. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other net income (expense) was net </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $5.3 million for the first quarter of 2024, compared to net expense of $14.5 million for the first quarter of 2023. The decrease in other net </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the first quarter of 2024 compared to 2023 resulted primarily from the non-cash remeasurement of the contingent earnout liability associated with the Company&#8217;s August 2021 merger with Alpha Healthcare Acquisition Corp.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss was $31.9 million for the first quarter of 2024, compared to $37.0 million for the first quarter of 2023. The current-period decrease in net loss resulted primarily from the non-cash remeasurement of the contingent earnout liability described above.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call and Webcast Details</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Humacyte First Quarter 2024 Financial Results Corporate Update</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Friday, May 10, 2024</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8&#58;00 a.m. ET</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conference Call Details&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Toll-Free&#58; 1-877-704-4453<br>International&#58; 1-201-389-0920<br>Conference ID #&#58; 13746046</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Call me</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> Feature (avoid waiting for operator)&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#026dce;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Click Here</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Webcast&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#026dce;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Webcast Link - Click Here</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company&#8217;s website for at least 30 days.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Humacyte</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humacyte, Inc. (Nasdaq&#58; HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte&#8217;s initial opportunity, a portfolio of HAVs, is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, AV access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte&#8217;s 6mm HAV for AV access in hemodialysis was the first product candidate to receive the FDA&#8217;s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte&#8217;s 6mm HAV for urgent arterial repair following extremity vascular trauma also has received an RMAT designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words&#58; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines&#59; our plans and ability to obtain marketing approval from the FDA and other regulatory authorities for the HAV and other product candidates&#59; the outcome of the FDA&#8217;s review of our BLA seeking approval of the HAV in the vascular trauma indication&#59; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials, including for our V007 Phase 3 clinical trial&#59; the characteristics and performance of the HAV&#59; our ability to manufacture HAVs and other product candidates in sufficient quantities to satisfy our clinical trial and commercial needs&#59; our plans and ability to commercialize the HAV and other product candidates, if approved by regulatory authorities&#59; and our anticipated cash runway. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and&#47;or competitive factors, and other risks and uncertainties, including those described under the header &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte&#8217;s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte Investor Contact&#58;</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joyce Allaire</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LifeSci Advisors LLC</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+1-617-435-6602</font></div><div style="margin-top:2pt"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">jallaire&#64;lifesciadvisors.com</font></div><div style="margin-top:2pt"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">investors&#64;humacyte.com</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><font><br></font></div></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte Media Contact&#58;</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rich Luchette</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precision Strategies</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+1-202-845-3924</font></div><div style="margin-top:2pt"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">rich&#64;precisionstrategies.com</font></div><div style="margin-top:2pt"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">media&#64;humacyte.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> </font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><font><br></font></div></div></div><div id="i43b603aa49c74459ad051caa58652a22_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><font><br></font></div></div><div style="margin-top:4.35pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte, Inc.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands except for share and per share amounts)</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.142%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,264&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,278&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,314&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,234&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses </font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,578&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,512&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations </font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(26,578)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22,512)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent earnout liability</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,593)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,191)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (net)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(725)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(266)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,318)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,457)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss and comprehensive loss</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31,896)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36,969)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.29)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.36)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding, basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,246,008&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,263,528&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="i43b603aa49c74459ad051caa58652a22_10"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><font><br></font></div></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte, Inc.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br>2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,505&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,448&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,421&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,926&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,278&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,653&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,791&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,059&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,313&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets </font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">161,466</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128,223</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,452&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,490&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,917&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,340&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,718&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,613&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,087&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,443&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue interest liability</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,959&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,600&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earnout liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,509&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,916&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligation, net of current portion </font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,850&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,293&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,909&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,425&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">135,314</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114,677</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock and additional paid-in capital </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595,362&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,860&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit </font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(569,210)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(537,314)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,152&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,546&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">161,466</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128,223</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>huma-20240510.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:108c879a-0b18-4eb5-9e60-c4f914c1e995,g:53f6320e-4e8c-4684-ba76-530d54434ca8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:huma="http://www.humacyte.com/20240510" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.humacyte.com/20240510">
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20240510_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20240510_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20240510_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.humacyte.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>huma-20240510_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:108c879a-0b18-4eb5-9e60-c4f914c1e995,g:53f6320e-4e8c-4684-ba76-530d54434ca8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.humacyte.com/role/CoverPage" xlink:type="simple" xlink:href="huma-20240510.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.humacyte.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_63a17a6c-0358-4dac-921e-175a05755f18" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntitiesTable_63a17a6c-0358-4dac-921e-175a05755f18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_273fe77b-1907-4406-9da4-9c6c35715e66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_63a17a6c-0358-4dac-921e-175a05755f18" xlink:to="loc_us-gaap_StatementClassOfStockAxis_273fe77b-1907-4406-9da4-9c6c35715e66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_273fe77b-1907-4406-9da4-9c6c35715e66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_273fe77b-1907-4406-9da4-9c6c35715e66" xlink:to="loc_us-gaap_ClassOfStockDomain_273fe77b-1907-4406-9da4-9c6c35715e66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_75a2ed16-6165-410c-b91d-671864fcf259" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_273fe77b-1907-4406-9da4-9c6c35715e66" xlink:to="loc_us-gaap_ClassOfStockDomain_75a2ed16-6165-410c-b91d-671864fcf259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a4253172-a695-47d2-80f9-9b1cc3a4675f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_75a2ed16-6165-410c-b91d-671864fcf259" xlink:to="loc_us-gaap_CommonStockMember_a4253172-a695-47d2-80f9-9b1cc3a4675f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_0d2eb41d-ddea-4e25-aa5b-36a2b742db5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_75a2ed16-6165-410c-b91d-671864fcf259" xlink:to="loc_us-gaap_WarrantMember_0d2eb41d-ddea-4e25-aa5b-36a2b742db5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_379fbe22-10f8-4352-9676-6c70ebec2102" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_DocumentType_379fbe22-10f8-4352-9676-6c70ebec2102" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a4c321ce-456f-463d-a21b-f2634df2cd06" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_DocumentPeriodEndDate_a4c321ce-456f-463d-a21b-f2634df2cd06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_010f8a2d-3f64-4239-9ab3-082976b7b4b7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityRegistrantName_010f8a2d-3f64-4239-9ab3-082976b7b4b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5a7c6a40-e28c-4500-bef8-835db10909dc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5a7c6a40-e28c-4500-bef8-835db10909dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_665a7703-be9e-40ad-8ffa-b184ac991e8c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityFileNumber_665a7703-be9e-40ad-8ffa-b184ac991e8c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a64360fe-910e-419d-a404-b4bbeb3be82a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityTaxIdentificationNumber_a64360fe-910e-419d-a404-b4bbeb3be82a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_43077525-623a-406f-a58d-4c6252db9a3e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityAddressAddressLine1_43077525-623a-406f-a58d-4c6252db9a3e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7dd24944-9c1f-405e-9fad-8c90d0d1777c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityAddressCityOrTown_7dd24944-9c1f-405e-9fad-8c90d0d1777c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d45ea2ea-097b-49f8-9f52-55f7629152c8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityAddressStateOrProvince_d45ea2ea-097b-49f8-9f52-55f7629152c8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_cbf0b2ad-ef02-44f7-9550-4f95503e6c7d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityAddressPostalZipCode_cbf0b2ad-ef02-44f7-9550-4f95503e6c7d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f8ce6ee7-539c-4043-bea3-57feb98519d4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_CityAreaCode_f8ce6ee7-539c-4043-bea3-57feb98519d4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_64eec89f-5f84-4c8d-b181-97d904ba8c9d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_LocalPhoneNumber_64eec89f-5f84-4c8d-b181-97d904ba8c9d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_8ca695f6-f8e7-4be2-b730-8dc4b64d8e39" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_WrittenCommunications_8ca695f6-f8e7-4be2-b730-8dc4b64d8e39" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_ba778dfe-99fe-4d4c-99f3-b196c8cacde0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_SolicitingMaterial_ba778dfe-99fe-4d4c-99f3-b196c8cacde0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_7966a4de-b292-45a7-9f36-33b1d7daf6b5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_PreCommencementTenderOffer_7966a4de-b292-45a7-9f36-33b1d7daf6b5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_cbdd7ba2-c4fa-4909-b1aa-e56da075aaa0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_cbdd7ba2-c4fa-4909-b1aa-e56da075aaa0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_58022fa5-21c9-4b05-aef3-1b43f1f6341e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_Security12bTitle_58022fa5-21c9-4b05-aef3-1b43f1f6341e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1693d293-8da6-452f-9677-5d7d428404b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_TradingSymbol_1693d293-8da6-452f-9677-5d7d428404b3" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_dc15a6c0-70a0-4a5e-8b69-4f62557492c0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_SecurityExchangeName_dc15a6c0-70a0-4a5e-8b69-4f62557492c0" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7ec22318-8dd1-4ca3-829f-bb6843856a93" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityEmergingGrowthCompany_7ec22318-8dd1-4ca3-829f-bb6843856a93" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_ef91f04a-e4b7-44c2-bbe9-b55d55b7e431" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityExTransitionPeriod_ef91f04a-e4b7-44c2-bbe9-b55d55b7e431" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d0774f3a-9921-4ee3-8b91-e4a7da814244" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityCentralIndexKey_d0774f3a-9921-4ee3-8b91-e4a7da814244" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b409c034-21bf-40ee-9e8d-c2e84c551083" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_AmendmentFlag_b409c034-21bf-40ee-9e8d-c2e84c551083" xlink:type="arc" order="22"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>huma-20240510_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:108c879a-0b18-4eb5-9e60-c4f914c1e995,g:53f6320e-4e8c-4684-ba76-530d54434ca8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityInformationLineItems_f31e47ca-3aa0-45b5-889b-6501d56cc9c7_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6ea3f733-5b00-40ab-852c-25d421bddbb9_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ff223b2b-1bb1-410f-b075-0b2c2a553600_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_38dc509d-2e41-400d-bf07-e4123b8da9ff_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_648d67e0-c938-49ea-97b3-73b7b2881444_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_bcdec0c7-071b-4115-adea-41b2e1a83ea6_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_322a7369-5aa8-404f-ab64-499bc3daa864_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e9222e9f-9769-4c67-b641-79f422f76db5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_9646d75b-94f2-4e5b-ad94-5c8111279eea_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_fdf9f27c-2c2b-4af0-b3a6-3aec35497a55_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3b7f6e01-39c9-4454-893a-6dc01489dacb_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5185f2d4-80d1-4ade-85ac-2f9e4e6ec05d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_0d68676e-6281-4341-9c6a-1c1a8480a410_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f775a955-55b6-4a88-9711-ff5574f80035_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_7f023bb5-dbff-4d2f-8fb4-2c89870f90eb_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_800caff6-4183-4b28-9def-5ccb6e9851d1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_046d40e3-f810-4959-acee-83bdfd3d8d86_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_944c1027-fb1d-4925-98ef-3d1ae8e0c7f6_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f5c0b3e7-e22b-4a4e-9cda-091f54d98120_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_0231d57d-8c77-4d39-afb7-aad5bf3cd98f_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ab3d6c84-2eea-4426-b3c6-97dd0d745dea_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f608a712-ae46-4461-afb9-e6640dceca81_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_16d557d4-233a-42d4-b779-eb764ae79e40_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_abe1adbf-1e8e-4d63-bf5f-76e791c375f4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_abaea730-3ef6-41e3-b97c-c9a6151a9cae_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_63e1d268-0ca3-4cad-892c-609b8418a314_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_65d8e72a-a300-4963-a667-479a94f006f1_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e3a1b159-5c65-4210-a125-0f0f457603a3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_7fc511d8-2baf-41d1-b636-7d56aae15da4_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>huma-20240510_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:108c879a-0b18-4eb5-9e60-c4f914c1e995,g:53f6320e-4e8c-4684-ba76-530d54434ca8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.humacyte.com/role/CoverPage" xlink:type="simple" xlink:href="huma-20240510.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.humacyte.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0f28676d-99f0-4efb-9343-0ca23f4c9da5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_63a17a6c-0358-4dac-921e-175a05755f18" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0f28676d-99f0-4efb-9343-0ca23f4c9da5" xlink:to="loc_dei_EntitiesTable_63a17a6c-0358-4dac-921e-175a05755f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_273fe77b-1907-4406-9da4-9c6c35715e66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_63a17a6c-0358-4dac-921e-175a05755f18" xlink:to="loc_us-gaap_StatementClassOfStockAxis_273fe77b-1907-4406-9da4-9c6c35715e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_75a2ed16-6165-410c-b91d-671864fcf259" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_273fe77b-1907-4406-9da4-9c6c35715e66" xlink:to="loc_us-gaap_ClassOfStockDomain_75a2ed16-6165-410c-b91d-671864fcf259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a4253172-a695-47d2-80f9-9b1cc3a4675f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_75a2ed16-6165-410c-b91d-671864fcf259" xlink:to="loc_us-gaap_CommonStockMember_a4253172-a695-47d2-80f9-9b1cc3a4675f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_0d2eb41d-ddea-4e25-aa5b-36a2b742db5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_75a2ed16-6165-410c-b91d-671864fcf259" xlink:to="loc_us-gaap_WarrantMember_0d2eb41d-ddea-4e25-aa5b-36a2b742db5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_63a17a6c-0358-4dac-921e-175a05755f18" xlink:to="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_379fbe22-10f8-4352-9676-6c70ebec2102" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_DocumentType_379fbe22-10f8-4352-9676-6c70ebec2102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a4c321ce-456f-463d-a21b-f2634df2cd06" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_DocumentPeriodEndDate_a4c321ce-456f-463d-a21b-f2634df2cd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_010f8a2d-3f64-4239-9ab3-082976b7b4b7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityRegistrantName_010f8a2d-3f64-4239-9ab3-082976b7b4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5a7c6a40-e28c-4500-bef8-835db10909dc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5a7c6a40-e28c-4500-bef8-835db10909dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_665a7703-be9e-40ad-8ffa-b184ac991e8c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityFileNumber_665a7703-be9e-40ad-8ffa-b184ac991e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a64360fe-910e-419d-a404-b4bbeb3be82a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityTaxIdentificationNumber_a64360fe-910e-419d-a404-b4bbeb3be82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_43077525-623a-406f-a58d-4c6252db9a3e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityAddressAddressLine1_43077525-623a-406f-a58d-4c6252db9a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7dd24944-9c1f-405e-9fad-8c90d0d1777c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityAddressCityOrTown_7dd24944-9c1f-405e-9fad-8c90d0d1777c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d45ea2ea-097b-49f8-9f52-55f7629152c8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityAddressStateOrProvince_d45ea2ea-097b-49f8-9f52-55f7629152c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_cbf0b2ad-ef02-44f7-9550-4f95503e6c7d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityAddressPostalZipCode_cbf0b2ad-ef02-44f7-9550-4f95503e6c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f8ce6ee7-539c-4043-bea3-57feb98519d4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_CityAreaCode_f8ce6ee7-539c-4043-bea3-57feb98519d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_64eec89f-5f84-4c8d-b181-97d904ba8c9d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_LocalPhoneNumber_64eec89f-5f84-4c8d-b181-97d904ba8c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_8ca695f6-f8e7-4be2-b730-8dc4b64d8e39" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_WrittenCommunications_8ca695f6-f8e7-4be2-b730-8dc4b64d8e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_ba778dfe-99fe-4d4c-99f3-b196c8cacde0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_SolicitingMaterial_ba778dfe-99fe-4d4c-99f3-b196c8cacde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_7966a4de-b292-45a7-9f36-33b1d7daf6b5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_PreCommencementTenderOffer_7966a4de-b292-45a7-9f36-33b1d7daf6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_cbdd7ba2-c4fa-4909-b1aa-e56da075aaa0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_cbdd7ba2-c4fa-4909-b1aa-e56da075aaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_58022fa5-21c9-4b05-aef3-1b43f1f6341e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_Security12bTitle_58022fa5-21c9-4b05-aef3-1b43f1f6341e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1693d293-8da6-452f-9677-5d7d428404b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_TradingSymbol_1693d293-8da6-452f-9677-5d7d428404b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_dc15a6c0-70a0-4a5e-8b69-4f62557492c0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_SecurityExchangeName_dc15a6c0-70a0-4a5e-8b69-4f62557492c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7ec22318-8dd1-4ca3-829f-bb6843856a93" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityEmergingGrowthCompany_7ec22318-8dd1-4ca3-829f-bb6843856a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_ef91f04a-e4b7-44c2-bbe9-b55d55b7e431" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityExTransitionPeriod_ef91f04a-e4b7-44c2-bbe9-b55d55b7e431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d0774f3a-9921-4ee3-8b91-e4a7da814244" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_EntityCentralIndexKey_d0774f3a-9921-4ee3-8b91-e4a7da814244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b409c034-21bf-40ee-9e8d-c2e84c551083" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2ef4d670-2fd4-45a4-8797-e5917d524ceb" xlink:to="loc_dei_AmendmentFlag_b409c034-21bf-40ee-9e8d-c2e84c551083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
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M;5:?]5";A.'$.M7Q-:JCJU1'5JH.KT#_J[A\3%-P4X_7 @        !) L+
MAJH"?4JP-MQ;&>&M#O-Z6!BV6!.&0\M4 >XJ_Z6J8QO5-V)T>%T
MD!@@#,R0UU)IY[67?#47?307=JMI"L.QU;@P'%BL\ENH.KY.77@+M $
M  "0+B ,#"A(U<7L547MU7 E#/L6J/:ZJ2X<U.BT,+<!        D"(@#+30
M**G48'7,?DWT/@TF#.%LA6'_HOO"X.NJ/+!"U5 -S@        !(#A"&IE'6
M4?%'5;$'-/P)@\]\I?<\>641. ,        @+4 8FD!1IX\_(HOSYUT8=LU5
M[IR#G $64 (        D! B#-9 M7#E2'Q\@%T88O&<K/6?+%?5PG@$
M  "0"B ,%J'TAN03-5<"ZN(#!#K#@(1AYRRE]UPYWA4         $ D0!HND
MGZM).%@MO##LF*$\OEF)]P8         Q "$P3Q%UV4)!RNL"$,DG\*P?88\
M)PWV9P        #$!X3!#%J5/O%(*4_"<-"*,,RY+PR>TY4[IL&%20
M (#X@#"8X69$V=5#)2R$(9@[8=@V37DE1(OW#         "$!80!1UFO33I4
M( 5AV#8#3C(         (@/"@)-QOB3Q<"%=8=C%HS!LG:+,3H-M&0
M   Q 6%X"$I/)1\K^$L8RL41AID/A&'W?!7>10         0$!"&ARBX5IEX
M.,]68=C,F3!LF0I7)0$       !B L+P$.FG<YL0!C^6PG!T%2MAF*PLRH2K
MD@        #1 &%XB)3C62R$(6PGC\(0N$.-]Q(         A *$X0&R2D72
M$5(8:GD4AH46A6'[7\*P!39D         ,0#A.$!1=<JN!2&C=P(P]8I( P
M      " :(@C#)K*<.6=-?+T*8KK<Y6YN_6R+/P>8I 1FG=/&'*;%H8];(5A
M.6-AV#()A $        0#:&%@5(6-"3^TA#S>7WT5_717>HN?U=[N7M-5$_Y
M[4T&O0:_M[!</Y.#A"%)8L+@ 6<8         /$05!@H3;G\2C=9S'](8:B)
M^KGANKN!$G-%H/2S69:$(=Y?R9\P[/D3A $       "0*((*@RICG"SV$TO"
M4'VIC[HL$F\C('P(PTD0!@       ,">$4X8*'5Y0]Q'UH6A-GX\WDQ F K#
M14&$82O,80        #$0SAAT)8=E\=U-"<,W4S"4'6I'Z5MP%L*Q</"4"R*
M,'@1PK 9-GL&        Q$,X8= 4>=$1!IVB!&\I%.GG<B4H#+ / P
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M%@8CE*9"4WY6G>^CRM^CK8Y#_XW?0R3DU2IVPA"Z@WMAV#9%KE;@/00
M    (1%'&*1,RLD"0A@:1!&&_<M %P        "1 6' *;]3SYDP;& O#%NG
MR^NJ8+HS        (#(@#&9(.4Y#&'S9"L,R6L)P>(,*[Q8         " X(
M@QFJ\Q0)AXO8",,VCH1AIEP'NR\         $@"$P3PWSE=@PA#GSZ,P^+H^
M$ ;/6?);"3J\0P         @!B ,YM%KJ:1CW C#B;7,A"%HEQKO#0
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M"$.HKSHK18]7Y)GZ&NK(%M7,7@U3>\JF_""C(PRF3.W9$+A;K=7 9P$
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M&(*$%0:E7'QAF-+#_K9B &$      $: ,-@C]0WR?W>=;'QID E,G.=IFL^
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M0O)MO+HY0!B80E,8BDNK\):29-7FHV3G&>79M@-=IGJ</!?;(*-U249-;4/
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M0L-CK_?A::J5">D* Z655<;-*;\PLDEAR M959UQ 6_/A/1SZ:R%(<);K=.
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M_ D]J)G56]Y8&*;8)@PH*\?Q,@=?2$ 86-"M/ZUQV/?]7?&6DN3 L0MDY\F
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MC5>W 'IOA$8FCYFQA>EB3606KMZ/5^>3N\)@T)3H4_Y." #3W!4&JF05?@1
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MSK-M!\Y:["-7J/ ^B0<( ]!" 6$0A;5;CS_;5KC+0Q]OXS37?4]=O1SOQSU
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M7TK!NP4 O"&:,,@3^S$7AHE-"D,.(0S*JG+\V%P0?]#\I&?.A:&RF,?-J@$
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MD5_(RY75 , (T82!TFMDL=];%H:!G B#HJH,/S!W7#FFY548/*?)=?!K @
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MBJ^.'LQ0&!8^$(;SFY65>7A182F^K0OQ4M 1AH,/"\/^A8H[B;Q/T08
M    IDA(& QWYT#7RC+65$09A6$P?6&H3 _2:R5QZ;]>9[@5K0O:K*0I#/Y+
M% E!6K@,"0       ) FTA(&(SI93OV-#551OS8I#/FA2ZO2 [6*&KR$V"!M
MR$O5Q9U4!VY4FA6&PRL4D0'JVPF@"@       ("DD:(P&*&T,E79Y?I;/M57
MEU9<FO&7,$PIO;2HXLK6VHQ 1=EU7C=RYHJ&*JKXCCXW39>;JLM)U15GZ>LJ
B*/Q.         "!)_A^6L1,=D>"BX@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139855010763424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>May 10, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 10,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Humacyte, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1763759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 East North Carolina Highway 54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Durham,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">313-9633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001818382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUMA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUMAW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( ,HXJE@9117U-P$  "<"   /
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M-_=%KLWC":[?#'!X=/X!4$L#!!0    ( ,HXJEAED'F2&0$  ,\#   3
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #*.*I8)!Z;HJT   #X 0
M&@              @ & $@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " #*.*I899!YDAD!  #/ P  $P              @ %E$P
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  "O%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="huma-20240510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humacyte.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="huma-20240510.htm">huma-20240510.htm</File>
    <File>huma-20240510.xsd</File>
    <File>huma-20240510_def.xml</File>
    <File>huma-20240510_lab.xml</File>
    <File>huma-20240510_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "huma-20240510.htm": {
   "nsprefix": "huma",
   "nsuri": "http://www.humacyte.com/20240510",
   "dts": {
    "inline": {
     "local": [
      "huma-20240510.htm"
     ]
    },
    "schema": {
     "local": [
      "huma-20240510.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "huma-20240510_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "huma-20240510_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "huma-20240510_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 2,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 30,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 26
   },
   "report": {
    "R1": {
     "role": "http://www.humacyte.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "huma-20240510.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "huma-20240510.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, par value $0.0001 per share",
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50",
        "label": "Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001818382-24-000054-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001818382-24-000054-xbrl.zip
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M6"H&[C$4689F6)II+09Y"$&FO330'%AH]Q]!Z1IRH-6]!T_6N5Y1C;)K.Z#
M!R46:I\'I<[)B%&W<S)F@A+\4F-_I?[=::D;A0)X0KN9Q3"#HYY.2X)-146B
ML-+YY9=?3H0O M89I;!9R I C\9)1;T\J:BAAY$[ZYRX_AU)Q"Q@IR773^*
MSMIA%#)8@#]M8T?&U4_?=5DH?T+[!3 F]QTU_U1<,^^TY&A ="$=XTC,;_="
MF&[6A=5Q&O1#ETW_8+,2\=W3DJ=9M5+' )IJFDV[:9U45D;=8I(SD \NRHB/
M ;TM$;7+IR4@B[;G3YFK>31 XLYFK9<Z'\\^#7IK$U96(>3,8QQ$$TL*-@:I
MN9U(1H E$4G=;0';<5I*_'$<X,;+=R..*U[9 WV:N+!#<K[%)-F<291R^20I
MK)V!+=>.8.?OF41L_N2[^.SYC!.Y)E8H,;K]/U81?O_C3OYJ=?08T!.Y^1/0
M-1<?0!1W$![-J&E(5??;YLMT'^B:M^3/^225%;B+T6"]-!HR:-@M4I5Z=&&R
M:1SXCB_.V7@(4[@^M$HM5LID=WL@ "3\IAO0)+GT!B)ROIY-_:34R;MTH_$X
M"F6#&N>D4CC\'!/S5;R.O;%?\=Y\H1S4A'CU^U)9E225)2%> 5&OY#UNE_^4
M]?+_*'$6WV0Z8NR'VHBAB=6NUF)Q//%=,0*[ROC?DNS7.4EB"D)TR%'*J=]J
MD/6A*+^%T8:1$-&X;<>BI#[.VYTHB'C[5T/^._8 0I#F8S^8M=_=P!XGY()-
MR'4TIN&[<@(J'LPE[GNJ8^+_A[5-6)]\FF0+AF%0F>< J%7__5>S;AROKG5I
ME8A6C0;^;=AV8)\9AU4*.@Q8WF$8<4"O!JL-:)RP=O[C.%>GRH+0Y$?'JT C
M!L$>%KY#@VP2.9]J7B!7-Q2"!6RC</.9LV8=FBKK[UM-O644-QFZ*=]7Y'@\
M;\S0HG8"O@%($"FG)3"W5H%=[!EQHQ21@=MT'%,7;?FV00#U\PDJ$O*'"4!$
M,< (F"A"]6X)HGF/(AKW*<)"-'^^Z-_T/I#!S=E-;[ 58>QCM8->]_-U_Z;?
M&Y"SBP^D]V?W][.+WWJD>WE^WA\,^I<7>P3!V B$+S09 =V(*"R3#WI7!^^M
M5FT]N.Q-Z.8GBZKE R.2) I\]ULX=$U$%\GW5\#8'R^OSS-QO[&'D0<AE+^E
M_ C0C$WMCW4GXF#086V$#I ;U[V+&W+=N[J\OMFCE-ALN5<I3U*PT8B(R( Y
MZ,P3TR81)V;MR'U/(N_@0;@9,5QZRGWAPZB]J3,"UY*1,T? \HG9LJL')*S7
M["4) YJAN-AK%D=<D*/\F5$P1%DB"+O#F!V7S<Q]WU8<1[9GN2MIX_:4Y;OJ
MW+OP1@-G2HSP,\VE,VT&"]!8./?U2YUS.B.F49:QP)TRZT_ELD/E<G!:8ML0
MUS6[]1,,,HH+:,GI#YSAW],Q=6:"E4D_=/2-*?!0&/VH-Z4@EQ!<Y&\^!Y/0
MA"0Q<] K=XD?$E\D!"09L#M__Y.Q#HVQ7@M>;4NW;/M1O.YKJ.HFN_W0UN:[
M9\53W+]UPK^/487,[^^+&<^1?B#:(@ZJ7B979*"M&Z6AX+-NY*XJ;4QG8<A+
ML)A'=SC.0EM7P:Y@ 9U0SAZ4D\+],3'\T0\8=!Z"A,RP)9,GIF:W:O9Z[N1'
M1]<-G?:SF+$CB7(5=W7PW6J:V:C;C5KK4>3MFJU!'G]_32Y1>"3Y$CVE2(P8
M)_\&!R1Q?>5"@=N$SKR_S,>R*[^EH?\?^?S^):AJC_C 3(R?8)* ('<112)O
M#<J^?JT/=-(;QT$T8UQN\RIK% *^N7%AO1[CPK+U:K6V$XM@AT-56WK3W,B4
M7*7'^B;T&#!O#9]S27Z 4>!M!?V9ZW*6)-E_GV \,Q?RC5+'JEDUTJ.)(!<1
M%R/2I1P,ZI"2WV'*"9V1VA,Q@0V$P*H]_BQ5(:N5]B$S=J-L,^1WX><EOXDF
M<X.N"09=RD=T7-ZM@5)$U/M#U[;!Y!6D2:5\R:_ &/9EN9#"7*O4N>C^M.J*
M<785@0,1_)\?*^\B"\<;P.Z-AFEO;\YM)$@/3K%GR,"H3,R!=OR8!H1-F9,*
M_PZ#-:#?6?+6S!G8=0#!9<^U5AZ+,3Z1T#H4%7FT.=N@2#[CC*XPBEGJM,PU
MK^?]MF+L4P0$<36*PGM^J6F5.K9I:ZVZ_3 O[A^W#X0[%W'<O__:M,S&<4($
M"UB,<))0 EHFP&U!BBQ#*"#W'CWN/\*]&1E=1(*<Q5C:A&SSC *8O>S/QX@#
M*67Q:"XC2_!(E2R$G?&(RJ:!(8WZE 1H_*DTU,9;M"?8NB/F?)65[32.>01"
M'?WU830E0Q9$$X0-&Q$#I*G]03P_0!+T$Z!'P4(78!81@#U. T%#%J5),",)
MN'B)-Y-?9A]$0]C'S,-70RY%]5,8!_ 9SO(V#WRW:(+?8<#.1W<Y:6^!R8-R
M#!]RS2S=:%@[<>9:=;UN-5\H4OS-=N\7&!@'3[Y-"V^N)+YP7P!M8J@E#;-X
M0_)DB;9IESK1VW 9BA&8H05@6,8+B9>*&ZY38)LJN*^*(\5JT0#6"AR9#=+]
M>$TLV]"A8X%%](,0V2"2];DPY3E(3!";P=,45GWC%+; "1EG2%DG+[-*P5Q;
MHK"56I0Y?55!<LF>/RZ)77&&,@P/:L@Z,%2W_-+ST.Q]BM1J;YS4 #>:LX2<
M)Z6:674UZVCX?C/"4WU_DEZ&W7Z2I(QO18#UGP1XCP!MIE6/G,T(,.O[#0&'
M0[."WU!-RS[\M"4S3#E.C(/K%1<5IDHIESE20%B'ZS>U6GJSVMRZ6,?4FT\X
M.YN_KQKUW=3J'.JB[,<]S#=50'2#AXQ50; S(@Z>N-M"X\S%P9M !:<R5#B8
MC8=1<+151/Y-(>(BJR&5),%R?0MB<C+RG9&,O2_DZ3;F7B8=I? LUB\'E=EX
M1B[,6G%WE?Z9F=90LMG<SFN4.NIT,9%G6\LDIIS<T2!EY&_2(#!)C,=O1]]6
M8/<$4?Y@NY&QM^+N^58T2YW?/Y^?_<3RCFD^-]-5D?W]NE(4*JLEI69+G;>Y
MH(E+_U)\0<XI_\H$^?3I\0S[4U*'.E]O>00NA);ARW$8\[PWLP'V)D+',DJ=
M:^8R-I;V:G:"/BDK*3\91?!RHEYB<IH[?B([>EA<&#(EC% K+$LN0@4!9&3]
M&>:W'=GI;Z:IUXQG<-63F_44N_U0FUTHTRQ3R;0O/]'_G7AM6V%G6=\H[ [<
M\>Z'+L9T&!G.B".3I;"NKR!DF"QHOI?)]!,I0P#66S2_@7PF8H2AH1BSFS0A
M+O-@"GEV225;C%KNJ]_+M*A3F38YPBQYXU@F7/+.OCSU%..I)TQ(J_B2-=2L
M@K&*CGK.!\58T^*[I6'U \];]XI1O%I1\-VBJ\^J(LU!^$U"T%4 % 56!4\7
MJL\N=:;//5*Z+Q;R'F$*+&PIY#!_K4Q@!/S# N;@A7QA)(->*2AJ[ 6(SHH1
M\,HU7P;"U$4U4NGC7,$,)Y<7^2$OA@ ;M'!V!\H>>ODA#1U,6%''P6-$V!EO
M4W,I=Q-5AN ^%'&SC^@\XK;,;OJK(L?IS1QWZOSST[>:/9K0/+1PX^$&J._=
M9K-%D'JC&L+E6Y/B2.UPF[. 8LWFVCU*BR7*M1F+3^@0/+Y4//S)-C6.]Z]F
MVNQFJ,;\9J@17SBOMTP;<D:_:M2#2=LTF-!9@DA[T>NCOIM4+2ZEZPLV)I9N
M6#JY9DD:"%F5>PE2+\M @>PB'^=BK1N!F,6&[6H&03C#3K;M^MZTQV4(YF2F
MV/,[%<ID]80[V%U)"M*9@J#&\F0@;D83J3Q ?,N"-4#/0L;S#&&H&U1+ I(#
M_N.)('^E\CPY40H%3%EGI&:W336[3LZ I^/9W&A:G11>>"D/_62$*T(#;.0/
M?4%:+=U$M2$_Z::<8]8PN\L"CX/E)7:X;XLS<3 &V)D,[$50C_.+&S<VSPYE
M%]%%\,/Y7:A2'5%I"2OHENM;E4)72*-"@$^?=1-1&7WW()#J?\@(A@"@#:MF
M+5B]'S!7_C:/Y=:"L@;AQ21CS)5U<T,;N8Q[1\>*"H[P@VR:Y<[9;._+:$NL
M;-KR;J&UCS9'5@OY8'%59O(OSRP'OF]7E#&2S6)U'8+$QQ Q)LD0RR_!]?+D
MT2-81'9=@K.ZFB1UP S*%E1 3!O>TV<47=2'CJ(&5,>I(]I).@:*G!T?D,QL
MZ8:I+TG&^1V-2F1F[)H<N@>$%P\]9ZVOPN@R&WJK];C1M?G[6JVQDWQJ RBG
M]OC=#B]1(S0W3KYW\"BCKC7:VM/1@51=D/K<DY([V9&]YC(_L,3A?KQBQ'U+
MSF YG:/75A(Z3^1T]DJLQ>(0K:N-B>/%0L/?&Z6>]V(E;FIQ+G.RFQG:TFS!
M7K F6JCL,Z/M>.\+) 47H$_9=-IJF?I(C&7UWL)B+Q-7FFS+M[:!1J5%Q[*+
M77VS^IBOOT8LGOSW?&)[J>]?(/EX6$6;IE$]T,11$9[&ONL&;%\'PR)8#;FB
MX''T,90#_(TG?#]00=7-)4=X,[GK9G\<!7P*]%+ZTEPD\H^HN-EEBDNYA*>3
M/M\M5E7HI1S*B</[FNQ9L3(\T'1PP;*#.8DZZ/]V<7;S^;KWVB(IRY?1J@3)
M7ZG/,P=VT]!&06;%38,9<6B*V1 9HE('6'&:(?B+L&'0$*DK%X=L1 ,/PPLX
MD-2[60<,TZ0A?".'HZD811R <]^<AUHS](:Y7<7O@W6ZNEG=S4'0JMXT6KM9
M4UUOV8\[VAOZNH7*LG7(!SZ*O2\L0^G^ZZ97)OV+;H%*V\XHW-(]+>RV?H7(
M#JX%.D#7#B]A;A.R>JGREF&  R*O8M/TG[/V@Z;ILR_=VA\X*F-222I@,8(P
M/]/)@**:>,Z)NF_AD>+BU5VYYOO +!9F/4PJ;P_>0Z&?5X,P62J["86\&HBZ
M(Y]Y2QF;2WG-%"\3U=#-LV[D [MC013+\YA9)YG3N0&')TEY$?GLWQ,]%*?3
M>MCIK*B_V"C_S&/GOU!+ P04    " #*.*I8J\V+QI4"  #]"   $0   &AU
M;6$M,C R-# U,3 N>'-DW55;;YLP%'[/K_!XG@,$TH:H2:6UFC0IVZJNU?HV
M&7,@5L%FMFG2?S_;B95+L[5(>YC&"^;X^\[]'"XNUTV-GD J)O@LB(=1@(!3
M43!>S8+[NX]X$ES.!X.+=Q@_?+A=H&M!NP:X1E<2B(8"K9A>(KT$]%W(1_9$
MT$U-="ED@_'<T:Y$^RQ9M=1H%(U2#_.W<AI'$SHYSPB.\GB"4\C'.(.S"-.T
MS.*4QI!EX_?5=)R49\DH H.84)R>35*<D_,S/$ZB8IRF24K)Q"E=JZFB2V@(
M,J%Q-5VK6;#4NIV&X6JU&JZ2H9!5.(JB.'SXO/CFH,$66S/^>(!>Y[+V^"2T
MUSE1X.'+KB$'<"N@SQJ&5#2A#3<:QR:C1&O)\D[#1Y.7:RA)5^M9T/&?':E9
MR: P2:_!IO4 L'>MB:Q ?R$-J)90>(/1^0 AFPO6M$)JQ%]02Z)R%UJG<$5(
M:ZE)@#:Y6PA*M&L)BU8&[C)QDA-"K9678"L9KE41A*]ZL%>..,NR<&WS>]J#
MD^5P>&R/.![A).YA]E 1XTH33J&/;?.%/>]O^+#KK7X^>%Y_'YPR!718B:>P
M /:6!CB&V\.)DA/.A79\*]G*VI;Q4FP$1F0=GWKO;Z'TX_IB!D^TB'M-B:12
MU*_T4]A*T8+4#-3^_#H%2PFE89OYP7YN?K02AL83#WEAX+ $]MI8 &5FU\6[
MV 7D5>CGUJA0I@XU;%+T+\=?0-DW?D-AG/T7T=<D[QN]H4#=,W!+O#/WB!6S
MX$J8_^\-J8QC5GY_^^GWZ]U9W!&\5J]W5XEYY)X8X=TO&R/'1)9Z$1X3CE1U
M"HJO?.[.QPV^)6\A?R!24M.N[L\[[*B3M*W09W*[9\+#1;/YWEM&3K#9<//!
M+U!+ P04    " #*.*I8=0\0^88(   #/@  %0   &AU;6$M,C R-# U,3!?
M9&5F+GAM;-V;6V_;.A+'W_LIO-G79<P[Q:#M03=M%\%I3X,F!SW8%X.7H2-4
ME@)):9)OOR/%;BYVT]92S\)Y<6R9YOPYO]%P2"K/?[M:%),O4#=Y5;[88_MT
M;P)EJ&)>SE_L_7GZEF1[O[U\]NSY/PCYZ]\?WTU>5^%B 64[.:S!M1 GEWE[
M-FG/8/*IJC_G7]SDN'!MJNH%(2_[GQU6Y]=U/C]K)YQRN6JV^K8^8#0+F;&.
M4,\R(L$K8D%3$F2R3 8&UJI_S0^42%IP"M@B"T3J3!+OC"9*T*BD%#*XK.^T
MR,O/!]V+=PU,<'AETW]\L7?6MN<'T^GEY>7^E:^+_:J>3SFE8KIJO;=L?K76
M_E+TK9FU=MI_^[5IDV]JB-VRZ5_OWYV$,U@XDI=-Z\IP:P#-Q_;K#^^J4=.;
M+[%IDQ\T_>_?5<&U/:#O#F'RS1;=)[)J1KI+A'$BV/Y5$_=>/IM,;CSGZE!7
M!7R$-%F^_?/CT;K2O&RG,5],EVVFKBA0<=]#>WT.+_::?'%>P.K:60WIF^I7
M0^Y$J4[./[O>IH,UG:&0.EQX('@5RB[$1]2XJ??AFK_V12(D=U&T(RI>[WM4
MO=7"Y6,Z>*WK$=3V'9$%+#S48TJ]U^\=G2N1#Q5V79Y=+%RX;F$_5(MI+^^P
MPDQ\[.;P ]+PQZ1+J%0QVFNX_?$=^P@Z+_,N=[S#C\L>.EO;*8&K%LH(-_EB
M9:.HPKU&19>MJJ_N+9R'HK\ZBY#/WI1MWEX?E=T4X9;"X*B%13/CD&34AA*>
MHB12.4EP8C $E&4F*BX#^'5 S0IX V%_7GV9HA6DQ$7WIG.1N$'TJ.T;GPT8
M40[-J?,%S+1PS#@="!4*I[/H K&< 6%&.:J,4HEEPP>Q,G=?]RWM5_5J!,O0
M_ZD,GNIJ,3JQMAK#93= 4//>I*HCU%BSX%?][7@0BJJ!^&*OK2_@]F)5MABV
M;PKHRA:\F6#>O=D6^$5#YLZ=STY:K'ZZC@X+US0?TDE;A<^OKG+TB1$)C/&$
M66J(E%03&]$Q-N@@E&$*M'XD ))K?,]G:>DF"J!HF]65VW#XKI@1P^.1R71#
MN&S'MOH5/MX4,0/AW]7SND_]/Z1H]F!*'XG^NIH1L7^S'KF%/C*NZI?X^N^)
M @QJ#I%IHIE61#(:B+<L$FU8IF4*B2N[H_3O57?_1_@_X^)? ;U:+*JR%_2^
MK_9F3G(EF.'$:8N"3.0DH\D2ZUD(PDEM5!J;^4,18R+?5"*O\QY*YB'H06Y=
MYTR'<O[DZMJ5[5(,C1R\Q+'$"(Y(X(HXISP1VG%O)(]^=,;W!.P\W^W=.>(]
MW%4GJ_VK4VP[$\8F#YP31A,6)T)Q8K7! 09#P4/@C/)!M?I=:W\?PU]4M&_M
MNA%OS[LZCJ'.J_BFC*]QZL%\$01G 7! .A&I122.,T\2UT+&Q$.DCY7=/\[R
MGMDG W5[9XY\@]Z,\2/,\Z;M4L8?;@$SVD69XY&(I'%T7. \X+P@-./6:&^\
M]&:$G8'[5G>>[6!7KJ/EP]$>E:&JSZNZ'V1?-AY6%V5;7Q]6$6;*F:"=I 1X
MM\VO*"4>,,-D0D7/J*4VAE'V@!X1\43 C^?H]3@0P^/@;5[ 'Q=]/: UJC%4
MH *+.8>Z2+*4'/$LDRY8RR ; _JMQ2=">$L7KN.4PW&>NJNCB!-)GO*;PZJE
M,*>ET#0!L:P[O&,6IQ)))<$\X\$+#QEW([#]AODG GH,YZY35\.IOXJQAJ99
M_NF&RV924&,4UO2:"ZSN*5803F61R*"YPMK>.K'AG.6GB6\P_41H#W7J.FD]
M&NE#?/NA/JTN<3T8(Y=6=CLY#(M$JC ,4Y=W@J611F:,&2-KKQE^6I2W=.@Z
M8S,:X[Y6^% ?U]67O PPBU(!+OT=H=9X(BU6"3;A@D^I9#2W3/$PPI'6-ZP_
M+=I#7+N./!L-^7'5M*[X;W[>UX;!)^HY1AXDRHF4R1"K%"4R=7\$X"(_C@?\
MGNVGA7M[MZ[#MD-@=UGF50VNUY&R !K $"4LEOY4=E6C$T29!-YF"LL(.0CO
M76L[#W1KUVW8&!FT[]4]!58<GU7EUYI? H3,)J)2AB,*6 Y@N<^(-=%2Z1W.
M&\-NTX<6=Y[E(!=NX#EHI^M3G;<ME-W1QT6YK.N;61:Z X^D2<HPS*0'3KP1
ME&0Q2*]ES$ \=H3X?:@;S>X\V>'.W(!WT&[7257D 9U8SM_CG%_GKIAY7*)G
ML5NN67R148;N':809G5 K2$"'<1VW>;.@QWHQ@U4!^U='=?0Q1A@\=:?A72/
MP]4?4L)<8JS63D8@GEO>C1"G]R0T$<*S:*)+VJM!=+]M>^<IC^36#;0';6T]
MD'74-!=0WQ47?(S&.]X]K8[+<DLM1J%S.%X='37*.3?LCOZ>@J=&?IB+-_ ?
MM,EU N$")Y9KQOUIWA8P4QGE/#E%. L6)Q2JB -,/<Q+D5C20K)A>UL/+>X\
MWT$NW,!ST%;6:>VZ_VPYN5[XJI@Q;47D5F YX#0.B:?N#!MK>TPKDF=8W7LQ
M".8]<SM/<GOG;< X:+=J%5-OKL*9*^?0'VS&P)33@1)#':ZIG0*2>8T1EC17
MRDC+P\#B:H/5G8<ZV)4;V(ZP+?5F ?4<@^T_=779GN$$<>[*ZYF!P+E@&<9<
M9+A:PX5WQG'QYKW.I,B4=G;8#?N(\9TG/99C-P ?M#6UU'6%Z:5L>I?>/(LR
M@V19HA)G>NF[!T<#+MX\X.RO5%3*&Y""C4%[S?)303W,I1L>_ABT?74CZA!K
MO-H51UC?7?T.U[-(C9%).%S!<8P\ (P\;QD*=%C;9TQR.6PO<J/9)T)XB#,W
MX!VTF_4*J_?85?!O"S>?>4EMH$)BD>>[HRS Q3IDD00.F0Q*,9H-R]3WS.T\
MSNV=MP'C<M?J^?2!-U#FYY?/EI>[E^X?@5\^^Q]02P,$%     @ RCBJ6(9/
MO0WQ#   "&T  !4   !H=6UA+3(P,C0P-3$P7VQA8BYX;6S%75UOVS@6?>^O
MX&;G81<H&U$B);&8=M#M=!;!=MJBS6 &6RP,?B9";2F0E";Y]TO)=N(/228I
M6WUI'.?Z'IYK'1_RFE1__N5^,0??55EE1?[J#+T(SH#*12&S_.K5V1^7O\'T
M[)?7SY[]_#<(__K7Y_?@UT+<+E1>@[>E8K62X"ZKKT%]K<"?1?DM^\[ ISFK
M=5$N('S=ONQM<?-09E?7-0B#$*_#UG\M7Z(@%6E"&0PX2B%6G$"JX@ *K"G"
M BE*R?.KER32<10&RD2D N(XQ9"S)(8D"B3!.,*"I6W2>99_>]G\PUFE@*&7
M5^VOK\ZNZ_KFY?GYW=W=BWM>SE\4Y=5Y& 31^3KZ;!5^OQ=_%[71B%)ZWO[U
M,;3*N@)-6G3^U^_OOXAKM6 PRZN:Y:(!J+*75?OD^T*PNJWZP7&!WHCF-[@.
M@\U3$(4P0B_N*WGV^AD RW*4Q5Q]5AHT/__X?-$+2<^;B/-<737O[2=59H7\
M4K.R?L^XFIO1M]GJAQOUZJS*%C=SM7[NNE2Z.^V\++>R-J.DS2A1W(SR[WU@
MYR.&?Z3QUOMC/<+@6KH?CC7&H9I^.-IP+\TGA#K]@#=@1@]Y>4&]R^54U^XC
MU.BAGW[$Q[HLBIK-)[@LGF VACQOGGAO'JU@FD0#'Z8MSNJC>V.HZKY6N53+
M3\NMU""3K\[,HYE4V>Q=7F?UPT7>.%O[L6V U46M%M5,1TCA1# 8,19 3(R!
MI2GE,"8!DB06@HID5C]>V3.5PS^^K ?1(MG G#FPK'O46JJJN"W%TN<,=./Q
MR]&\7@*##63PM<$&+?C_?CY_&JUWH>83T9]/PKP06PCSQLZ+<I=8(2R)/8FD
M,LQ:5I42+ZZ*[^<F@6$71LT#V#QHM7$@[?G>V_2F7(^8E>) '5<1YZ(PLY:;
M&FZ55)?%PH5:7;B\P\MRF@&<@:*4JC2ST@XR6]?<>E+Z^#G\J_G4F,6*13J)
M(DAX8'09, Y3$@H8$HE#Q*7DG-KJLA/AQ))\G&HO08%!!0VLO1:[ZW)8AJ/9
MNBG0F:B3] ;)>*FN.^-D@ALDM*FUX4 WF=U6\(JQF]G;8K$H\B]U(;[]KA9<
ME3.MPS#B(8>(<P0Q"C3D04+,<BX4(2,DBH/ 1F:]"">6V1(/M(#/P0TKP7<V
MOU7@I^!%8%9QX$:5H+IFI:7N^@LUK+NCT'?3W29S\'6)=@2_.\BD0W2:5;SE
MLGKQ4GEJ7E?K9YXDV)]_$@D>I+>6X.% =Z?[5*HFG3(C;)1]V4Q=RX]:F\LK
M2J4@ 35S:(6-#H- 0JZ#!)K?C#Y3R:C6MG;7#W-B,1I@*#:0P1(:M-CVQC=0
MIL/N=QSR;E+TX^WD@X=I>9GA0-K)'/$PM4U;M(CV],8YJZJ/NE7ZK\6"9?DL
MQJF,$Q5 0:,48JH8I F/8!+QA(=IBC#&3N:X!W%J=VP 0:'7+K$$M5P/#A3&
MT@Q'T75T0T>F[G[82^98AK@/,*TC]A+<L\3^2'=/_%+,,Y'567[UNYG?EAF;
MS[B02@0B@4&"N)F3(@*9--K#B(<*L312++;UPOWT)Y;<$R!8(]H[7T<Q#CO>
M.(IN,G-AY^1O_22\?*TCW61^UD]ET\<&HMQ%]#:K']Z4BKTMI)I%8<B2**:0
M,&9<*\ :,AYCXU^4BTB:)V,KU]I-?&JO:OIX#19HP.PUL\7]L%I\&3G:D1T9
M)XETC=Q+'%N))I-%U_ W!='Y=W<I+%N4;Z0T[T[UJ:AJ-O]O=M->'(J&8:BH
M-I,XHPXLX@0:72"84(W#4">QY,2MU=\%,TVK?X7\'"RQ@0%WU,U H6Q;_6/I
M>[7ZG9E[M/J'B(UH]7>FG;C5/T1MO]4_&.TKSK=FW5:R^859N=W_1SW,:(QC
MF1 .*=8AQ,H\8I)B2$2*$ H3JA1ST^4.PC227(&"%A486%<M[M;%5H8CV'HI
MT)ZHA_1ZR(Q0W6[&B0770VA?:WV!(SVP\=6/Y65QE\^TU%2'B8"A",W"BND
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M )('0A_'4@2(-J!US4SP)[<0@/% F7*IM)Y)"\!/@69WPD E5(K747(#>__
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M*B?*)*P=J[40IX)AA^\) B4)#V^4"T%@\[>!2 )\X"6/,0\,"PFYNJ"4^A\
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M;6$M,C R-# U,3 N:'1M4$L! A0#%     @ RCBJ6*O-B\:5 @  _0@  !$
M             ( !9A   &AU;6$M,C R-# U,3 N>'-D4$L! A0#%     @
MRCBJ6'4/$/F&"    SX  !4              ( !*A,  &AU;6$M,C R-# U
M,3!?9&5F+GAM;%!+ 0(4 Q0    ( ,HXJEB&3[T-\0P   AM   5
M      "  >,;  !H=6UA+3(P,C0P-3$P7VQA8BYX;6Q02P$"% ,4    " #*
M.*I8]I\I334(  #:0   %0              @ $'*0  :'5M82TR,#(T,#4Q
M,%]P<F4N>&UL4$L! A0#%     @ RCBJ6.IMT3PN)0  $%T! !@
M     ( !;S$  &AU;6$M,C R-# U,3!X97AX.3DQ+FAT;5!+!08     !@ &
+ (T!  #35@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>huma-20240510_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="huma-20240510.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
        </entity>
        <period>
            <startDate>2024-05-10</startDate>
            <endDate>2024-05-10</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-10</startDate>
            <endDate>2024-05-10</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-10</startDate>
            <endDate>2024-05-10</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001818382</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-26">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-05-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Humacyte, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-39532</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">85-1763759</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">2525 East North Carolina Highway 54</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Durham,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">27713</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">313-9633</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-2" id="f-17">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-18">HUMA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-20">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-21">HUMAW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-22">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-24">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
